Great summary David on a cool abstract by Kevin Winthrop- unfortunately we still lack any predictive biomarker of clinical protection from VZV - so though intriguing we desperately need clinical vaccine studies in OUR patients. Lastly I am not impressed/concerned about Ab responses since there is virtually no data on their protective effect here. Hypogamma pts do quite well w VZV risks.- CME is where is where its at ..............
Great summary David on a cool abstract by Kevin Winthrop- unfortunately we still lack any predictive biomarker of clinical protection from VZV - so though intriguing we desperately need clinical vaccine studies in OUR patients. Lastly I am not impressed/concerned about Ab responses since there is virtually no data on their protective effect here. Hypogamma pts do quite well w VZV risks.- CME is where is where its at ..............